Today, we look at the latest Elixinol news, along with recent announcements out of MGC and BOD. We conclude that Elixinol could encounter support in the coming weeks or months. Meanwhile, MGC and BOD remain exciting but more speculative cannabis plays.
At time of writing, the share price of MGC Pharmaceuticals Ltd [ASX:MXC] is holding steady at 5.3 cents. The company spiked in late in 2017, along with other ASX-listed cannabis companies...
At time of writing, the share price of Elixinol Global Limited [ASX:EXL] is up 1.45% trading at $3.50.The Elixinol share price registered a small gain today after four straight losing sessions
Today, the Elixinol share price was trading down initially but was able to register a small uptick when the announcement was released, and then settled where it started at $4.As per the announcement, the Manufacture licence allows Elixinol’s subsidiary to manufacture...
Elixinol has focused much of its operational efforts to rapid global expansion over the past couple of years. In 2019 alone, the company has managed to expand operations across Europe, including the Netherlands, Spain and United Kingdom (a cannabis market predicted to be worth €115.7 billion by 2028). It entered the New Zealand market and significantly expanded US operations via capital raisings and acquisitions.
In an announcement made this morning, EXL said it will issue approximately 12.8 million shares at $3.90 per share, representing an 8.7% discount to the closing price on Monday. We look at Elixinol's prospects going forward.
At time of writing, Elixinol Global Limited [ASX:EXL] is down 2.43%, trading at $3.21. The latest news out of the company is that it has purchased new land for its proposed manufacturing facility and renamed its Australian medical cannabis company.
As an investor, it presents a once in a lifetime opportunity. A chance to be a part of a revolution that is set to change the world forever.